Author: Editor

Philip Philip, MD of Karmanos Cancer Institute discusses duration of therapy and whether or not shorter treatments will have the same outcomes for patients with stage III colon cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses the use of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses the possible benefits of the use of immunotherapy in gastrointestinal diseases at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute gives his take on the use of capecitabine in biliary cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Philip Philip, MD of Karmanos Cancer Institute discusses the impact of PEGPH20 on care of patients with metastatic pancreatic cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Daniel Petrylak, MD of Yale School of Medicine discusses which tests patients with urothelial carcinoma should receive as part of their cancer care at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Daniel Petrylak, MD of Yale School of Medicine discusses what’s next for patient with bladder cancer after checkpoint inhibition therapy at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Daniel Petrylak, MD of Yale School of Medicine discusses the role of checkpoint inhibition therapy in urothelial carcinoma cancer at the 2017 Annual Meeting Annual Meeting.

Daniel Petrylak, MD of Yale School of Medicine discusses whether or not prostate cancer guidelines should be updated based on the new results of the LATITUDE study. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses the collaboration between COTA and IBM Watson Health at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses the implications of healthcare and reimbursement reform on technologies and innovates at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses what tools do oncologists need as they move from fee for service to value based reimbursement at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew L. Pecora, MD, FACP, CPE of John Theurer Cancer Center discusses how healthcare reform and the move from volume to value progressing in oncology at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology explains what utilization management is and why it is important in cancer care at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses implementing an informatics-enabled oncology practice at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the future of the 340B program, which requires pharmaceutical companies to provide outpatient drugs to eligible health care organizations significantly reduced prices. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses the importance of patrolling drug costs and reimbursements for Texas Oncology at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Debra Patt, MD, MPH, MBA, VP of Texas Oncology discusses why she has not been incorporating liquid biopsies into patient management at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the collaboration between the Association of Community Cancer Centers (ACCC) and OCM and how ACCC is supporting other practices that are participating in OCM. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the challenges and solutions Lancaster General Health is finding as it participates in OCM at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses the major themes coming out of Oncology Care Model (OCM) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Randall Oyer, MD of Ann B. Barshinger Cancer Institute and Lancaster General Health discusses how Oncology Care Model (OCM) is helping the health care system at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health gives an overview of the data demonstrating clinical utility for Watson for Oncology (WFO) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health discusses future developments for IBM Watson at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health discusses IBM Watson’s library of tumor types and what it takes to add a new tumor at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health explains how the Watson for Clinical Trial Matching tool matches patients to clinical trials at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School discusses the use of vemurafenib in BRAF+ mutated metastatic colorectal cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School explains whether or not selective internal radiation therapy (SIRT) is effective in treating metastatic hepatocellular carcinoma (HCC) at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School discusses the optimal duration of therapy for patients with stage III colon cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Jeffrey Meyehardt, MD of Harvard Medical School discusses how immunotherapy is being studied and implemented in the treatment of gastric and esophageal cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses how he identifies and chooses the right patients for abiraterone and enzalutamide at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses whether or not AR-V7 is ready for prime time at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center compares the three trials, CHAARTED, STAMPEDE, and LATITUDE, and discusses how clinicians choose between chemotherapies for patients with prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses the impact of cost with the introduction of abiraterone as standard of care for patients with prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Christopher J. Logothetis, MD of MD Anderson Cancer Center discusses why the LATITUDE study will be practice changing for the treatment of prostate cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Kathryn Kolibaba, MD of US Oncology Research discusses the general takeaways from the oral sessions on lymphoma presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Kathryn Kolibaba, MD of US Oncology Research discusses the MAGNIFY study and its impact on high-risk indolent NHL patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Kathryn Kolibaba, MD of US Oncology Research gives an overview of the results from the BRIGHT study and its impact on treatment for indolent non-hodgkin lymphoma patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute discusses the use of immunotherapy combinations for future treatment of patients with lung cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute discusses the use of gefitinib versus standard chemotherapy for patients with stage II-IIIA non-small cell lung cancer with an EGFR mutation. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted therapies in treating lung cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Edward Kim, MD of Levine Cancer Institute discusses the biggest updates in lung cancer research, which include the breakthrough of immunotherapy and the approval of new biomarkers. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the APHINITY trial and its impact on clinical practice and future treatment for breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the differences and similarities between CDK 4/6 inhibitors at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses how immunotherapy is being studied and integrated into the treatment of metastatic breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Mohammad Jahanzeb, MD, FACP of Sylvester Comprehensive Cancer Center discusses the impact of the MONARCH-2 trial on treating patients with metastatic ER+ breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai gives an overview of the most promising studies on myeloma presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai discusses what physicians should be aware of when sequencing agents in multiple myeloma treatment. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Sundar Jagannath, MD of Icahn School of Medicine at Mount Sinai explains how personalized medicine will impact the treatment of multiple myeloma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center discusses the impact of immunotherapy for the treatment of gastric and GE junction cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center discusses whether or not stage III colon cancer patients should be treated with either 3 months or 6 months of FOLFOX therapy. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center discusses new peri-operative treatment regimens for resectable gastric and GE junction cancers at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Howard Hochster, MD of Yale Cancer Center gives an overview of treatments for BRAF-mutated positive colorectal cancer patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Patricia Goldsmith, CEO of CancerCare discusses the new data on patient-focused initiatives presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Patricia Goldsmith, CEO of CancerCare discusses the tools that cancer patients should have as they progress on their journey. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Patricia Goldsmith, CEO of CancerCare discusses the financial programs that are provided by CancerCare for cancer patients to help with treatment and cancer care costs. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute discusses the use of pembrolizumab in tumor-agnostic MSI-high patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute gives an overview of the promising data presented at Annual Meeting on resected biliary tract cancer (cholangiocarcinoma). This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute discusses the optimal duration of therapy for a stage III colon cancer patient. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Richard M. Goldberg, MD, FAnnual Meeting of West Virginia University Cancer Institute explains how he defines a high-risk from a low-risk stage III colon cancer patient at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains the use of checkpoint inhibitors is changing the treatment standards for renal cell carcinoma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses his thoughts on sequencing when treating patients with metastatic renal cell carcinoma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains how he stratifies metastatic RCC patients to choose the most appropriate treatments at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute gives an overview of the promising data on renal cell carcinoma presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute discusses the future impact of new therapies for renal cell carcinoma treatment at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists gives an overview of the phase III study, the APHINITY trial, and its impact on future clinical practice and the treatment of adjuvant breast cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists gives an overview of the new approaches in treatment of breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists discusses how CDK 4/6 inhibitors are changing the treatment of breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Neelima Denduluri, MD of Virginia Cancer Specialists explains how the results of the MONARCH-2 study will change future treatment of breast cancer at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses the difference in side effects between abiraterone and chemotherapy at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses how physicians should treat hormone-sensitive advanced prostate cancer patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital gives an overview of the STAMPEDE study, which focuses on the use of abiraterone acetate in the treatment of prostate cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses her thoughts on the LATITUDE study for prostate cancer, which was presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses how she reliably identifies subgroups for targeted therapies in HCC at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania gives an overview of what she learned from the phase III trial, Checkpoint 459, on the use of nivolumab in advanced HCC. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania explains how new agents being studied will be integrated into clinical practice for the treatment of advanced HCC at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Nevena Damnjanov, MD of Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania discusses the use of lenvatinib in the first line setting for the treatment of hepatocellular carcinoma. This was recorded at the 2917 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center gives an overview of the LUX Head and Neck 2 trial, which was presented at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center explains the use of bevacizumab plus chemotherapy for the treatment of patients with metastatic head and neck cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center explains whether or not patients with head and neck cancers should be tested for PD-L1. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Barbara Ann Burtness, MD of Yale Cancer Center discusses how immunotherapies are being integrated into head and neck cancer treatments at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Phil Bonomi, MD of Rush University Medical Center discusses how immunotherapies are being integrated into the treatment of small cell lung cancer and mesothelioma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Phil Bonomi, MD of Rush University Medical Center discusses whether or not MET inhibitors are effective in the treatment of metastatic non-small cell lung cancer. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center discusses which novel agents to use in the treatment of multiple myeloma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center discusses personalized medicine for the treatment of multiple myeloma patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center explains how immunotherapies are being integrated into treatment of multiple myeloma at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Noa Biran, MD of John Theurer Cancer Center discusses induction therapy for treatment of multiple myeloma patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group explains whether or not the Watson for Clinical Trials Matching tool will increase work flow at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses how the Watson for Clinical Trials Matching tool work at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses the design of the Watson for Clinical Trials Matching tool at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health explains whether or not ALK inhibitors can be sequenced in clinical practice at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health discusses what physicians should expect when treating ALK positive lung cancer patients with ALK inhibitors at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health explains how to choose one ALK inhibitor over the others at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Lyudmila Bazhenova, MD of UC San Diego Health discusses the reliability of the ALK biomarker and whether or not physicians can trust the test in their clinical practice. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses some of the challenges in treating elderly acute myeloid leukemia patients at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses the use of the Leukostat test in clinical practice, which was approved with midostaurin at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses the approval of midostaurin for FLT3+ AML patients. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

Aref Al-Kali, MD of Mayo Clinic discusses the important data presented on FLT3 mutant AML at the 2017 Annual Meeting Annual Meeting in Chicago, IL.

An educational overview of facts in Childhood Cancer | Pediatric Oncology (an educational tool designed to be shared by healthcare professionals with patients and caregivers)

Overview of facts in breast cancer (an educational tool designed to be shared by healthcare professionals with patients and caregivers)

H. Jack West, MD of Swedish Cancer Institute gives an overview of the use of gefinitib compared to standard chemotherapy (vinorelbine+cisplatin) as adjuvant treatment for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8500: Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104)

H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced nonsquamous non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9094: First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a third generation ALK inhibitor, lorlatinib, for ALK positive non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9006: Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study

H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA9007: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial

H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take home of the POLLUX and CASTOR trials, which is the importance of early triplet therapy for relapsed patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on the RESONATE trial is the role of ibrutinib for all types of CLL patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take-home message of the LATITUDE study at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked at daratumumab in combination with lenalidomide plus dexamethasone (DRd) and bortezomib plus dexamethasone in relapsed and refractory multiple myeloma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on androgen deprivation therapy (ADT) with abiraterone in newly diagnosed, high-risk, metastatic prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview a four year follow-up study on the use of ibrutinib in previously treated patients with Chronic Lymphocytic Leukemia (CLL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology summarizes common questions that are asked regarding the updates study on the RESONATE trial, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains a common question that’s usually asked regarding the CASTOR/POLLUX study, which is whether or not you can split the dosing of daratumumab. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status

Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate cancer: androgen deprivation therapy plus abiraterone or androgen deprivation therapy plus docetaxel. He argues ADT plus abiraterone, but it ultimately depends on the physician and patient. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer

Katja Weisel, MD of Janssen Oncology gives an overview of her abstract, which focuses on two randomized phase III trials in relapsed or refractory multiple myeloma. DRd (POLLUX) or DVd (CASTOR) significantly improved PFS and deepened responses compared with Rd or Vd alone. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status

Katja Weisel, MD of Janssen Oncology explains further the next steps for the POLLUX and CASTOR trials which include extending the investigation of monoclonal antibodies in front line treatments. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Katja Weisel, MD of Janssen Oncology discusses the impact of the POLLUX and CASTOR trial on clinical practice, which are both already introduced in daily practice. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Katja Weisel, MD of Janssen Oncology summarizes a poster presentation that focused on the anti-CD38 antibody in refractory myeloma patients which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the next steps for the clinical trial at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy

Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the impact of atezolizumab on clinical practice and future clinical research at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy

Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of the practice-changing data on lung cancer at the 2017 ASCO Annual Presentation in Chicago, IL.

Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of her presentation, which focuses on the use of atezolizumab in advanced non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy

Jalaja Potluri, MD of AbbVie Inc. discusses what’s next for her study and her hopes for the drug to become FDA approved. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jalaja Potluri, MD of AbbVie Inc. discusses common questions colleagues ask regarding her study at the 2017 ASCO Annual Meeting in Chicago, IL.

Jalaja Potluri, MD of AbbVie Inc. gives an overview of her abstract, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS7069: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia

Jalaja Potluri, MD of AbbVie Inc. discusses the treatment trends for 2017 in acute myeloid leukemia at the 2017 ASCO Annual Meeting in Chicago, IL.

Nathan Pennell, MD, PhD of Cleveland Clinic discusses what’s next for his study on maintenance pembrolizumab for patients with small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8504: Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)

Nathan Pennell, MD, PhD of Cleveland Clinic gives an overview of his abstract, which focused on the use of maintenance pembrolizumab in patients with extensive stage small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8504: Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)

Nathan Pennell, MD, PhD of Cleveland Clinic discusses common questions that colleagues ask him regarding pembrolizumab, which is if there is a biomarker that can let clinicians know which patients will respond to the drug. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nathan Pennell, MD, PhD of Cleveland Clinic summarizes promising presentations on targeted treatments in patients with non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. gives an overview of Advaxis’ Lm Technology, which alters Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T-cells directed against cancer antigens. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains what axalimogene filolisbac is and the use of it in cervical cancer, specifically in the AIM2CERV trial. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the pipeline of Lm Technology at the 2017 ASCO Annual Meeting in Chicago, IL.

Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains how Lm Technology works in the system and what are the advantages of the technology at the 2017 ASCO Annual Meeting in Chicago, IL.

Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the practice-changing studies on immuno-oncology coming out of ASCO 2017. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and Advaxis that is designed to activate a patient’s immune system to respond to certain mutations in the tumors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health discusses the future of Watson for Oncology in clinical practice at the 2017 ASCO Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health summarizes the use of Watson technology in the field of oncology at the 2017 ASCO Annual Meeting in Chicago, IL.

Andrew Norden, MD of IBM Watson Health discusses questions and concerns colleagues have regarding Watson for Oncology, which include whether or not physicians will be replaced in the future due to this type of technology. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Aly-Khan Lalani, MD of Dana-Farber Cancer Institute discusses the next steps for his study, which include combining c-met targeted therapies with immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression

Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of his presentation, Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression, at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression

Aly-Khan Lalani, MD of Dana-Farber Cancer Institute summarizes the common questions colleagues ask him concerning his study on c-Met expression in renal cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression

Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of practice-changing data coming out of ASCO on metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute gives an overview of his abstract, Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC), at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)

Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses common questions colleagues ask him regarding his abstract at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)

Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses the impact of his study on clinical practice and future clinical research. He talks of his hopes for the increase in testing for the mutation and in utilization of MET inhibitors to patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute summarizes the next steps for METdel14 mutations and MET inhibitors for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group gives an overview of his presentation, which focused on the use of IBM Watson technology for clinical trial matching at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6501: Cognitive technology addressing optimal cancer clinical trial matching and protocol feasibility in a community cancer practice

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses common questions colleagues ask him regarding the IBM Watson platform at the 2017 ASCO Annual Meeting in Chicago, IL.

J. Thaddeus Beck, MD, FACP of Highlands Oncology Group discusses the impact of IBM Watson on clinical practice and future research at the 2017 ASCO Annual Meeting in Chicago, IL.

Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL. Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC) and advanced melanoma: Phase 1 KEYNOTE-029 study

Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his second presentation, which focused on the use of nivolumab plus an anti-LAG 3 antibody for the treatment of metastatic melanoma at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9520: Initial efficacy of anti-lymphocyte activation gene-3 (antiLAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiPD-1/PD-L1 therapy

Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses what the next steps are for these two clinical trials and the impact of these studies on future clinical practice and research in metastatic melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Rini, MD of Cleveland Clinic gives an overview of the poster presentations on kidney cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Rini, MD of Cleveland Clinic gives an overview of his poster presentation which focuses on the use of sunitinib in advanced/metastatic renal cell carcinoma at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4597: Phase 3 KEYNOTE-426 trial: pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naïve advanced/metastatic renal cell carcinoma (mRCC)

Brian Rini, MD of Cleveland Clinic discusses the treatment trends for kidney cancer in the next couple of years which include combination therapy at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia discusses the take-home message of the AIM2CERV trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia discusses how he communicates and encourages his patients to participate in clinical trials, specifically the AIM2CERV trial. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia gives an overview of poster presentations he found the most interesting and exciting at the 2017 ASCO Annual Meeting in Chicago, IL.

Sharad A. Ghamande, MD of Medical College of Georgia discusses the unmet need for cervical cancer and the promising data coming out of the AIM2CERV trial, especially for patients with high risk of recurring disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of the treatment trends for 2017 in breast cancer treatment. He discusses two promising clinical trials on breast cancer that were presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses the next step for RAD1901 and his plans for the next trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center gives an overview of his presentation, Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer

Aditya Bardia, MD, MPH of Harvard Medical School and Massachusetts General Hospital Cancer Center discusses common questions he’s asked regarding his study on the use of elacestrant (RAD1901) for ER+ advanced breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 1014: Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer

Adi Diab, MD of MD Anderson Cancer Center discusses the treatment trends for 2017 in oncology, which include combining immunotherapies with chemotherapy at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center gives an overview of the promising data on intratumoral therapy that was presented at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center discusses the impact of cytokine therapy and NKTR-214 on clinical practice and future clinical trials, specifically its role in combination with other treatments at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center discusses a common question he’s asked, regarding the use of NKTR-214 for not only renal cell carcinoma and melanoma, but for other cancers as well. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Adi Diab, MD of MD Anderson Cancer Center gives an overview of his abstracts, which focus on the use of NKTR-214 for treatment of patients with renal cell carcinoma and melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract e14040: A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors Abstract 2545: Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses whether or not there is a phase 3 trial in the works for the use of gilteritinib for treatment of relapsed/refractory acute myeloid leukemia. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology the future of treatment for metastatic urothelial cancer at the 2017 ASCO Annual Meeting in Chicago, IL.

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses a phase 1 study of enfortumab vedotin for metastatic urothelial cancer, which was presented by Daniel Peter Petrylak, MD of Yale Cancer Center at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 106: A phase 1 study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of the results of the FAST Phase 2 Trial, which was presented by Martin H. Schuler, MD at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4028: Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction (GEJ), and esophageal cancers: Results from the FAST Study

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses the use of enzalutamide for men with metastatic castration-resistant prostate cancer. This abstract was presented by Gerhardt Attard, MD, PhD of The Institute of Cancer Research at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 5004: A Phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology gives an overview of an abstract presented by Jessica K. Altman, MD of Feinberg School of Medicine at Northwestern University, which focuses on gilteritinib for FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Abstract 7003: Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance gives an overview and background context on her abstract which focuses on t-cell therapy merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 3044: Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance discusses what’s next in the future for her clinical trial on t-cell therapy and avelumab for merkel cell carcinoma at the 2017 ASCO Annual Meeting in Chicago, IL.

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance explains what epitopes are in merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Kelly Garneski Paulson, MD of Seattle Cancer Care Alliance gives an overview of her poster presentation which focuses on two trials of cellular immunotherapy for merkel cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance discusses the promising data coming out of SCCA for acute lymphoblastic leukemia (ALL) and lymphoma at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance stresses the importance of patient advocacy, quality of life, and cancer care for patients and survivors at Seattle Cancer Care Alliance. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance gives an overview of a joint session between American Association of Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) on two types of liquid biopsies, circulating tumor cells and circulating tumor DNA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Nancy E. Davidson, MD of Seattle Cancer Care Alliance discusses plans the center has on the future of cost and affordability for cancer care at the 2017 ASCO Annual Meeting in Chicago, IL.

Shinji Atagi, MD of National Hospital Organization Kinki-Chuo Chest Medical Center gives an overview of a randomized trial done by the Japan Clinical Oncology Group on radiotherapy for elderly NSCLC patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8532: Randomized trial of thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer (NSCLC): Long-term follow-up of Japan Clinical Oncology Group (JCOG) Study JCOG0301

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. discusses what’s next for entrectinib and his hopes to launch the drug globally in the next couple of years. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. gives an overview of his clinical trial, STARTRK-2 and the use of entrectinib, an investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors, at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains the impact of Entrectinib and the STARTRK-2 trial on clinical practice and future clinical trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. explains genomic testing in finding patients for the clinical trial, STARTRK-2. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. STARTRK-2: A Phase II Study on Use of Entrectinib in NTRK1/2/3, ROS1, or ALK Gene Fusions

David Michael Hyman, MD of Memorial Sloan-Kettering talks of his hopes for LOXO-101 in future clinical practice and clinical trials at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers

David Michael Hyman, MD of Memorial Sloan-Kettering gives an overview his presentation, which focuses on the efficacy of larotrectinib (LOXO-101) in adult and pediatric TRK fusion cancers at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David Michael Hyman, MD of Memorial Sloan-Kettering explains common questions physicians ask him concerning his study on the efficacy of larotrectinib (LOXO-101). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers

William P. Harris, MD of Seattle Cancer Care Alliance gives an overview of some of the promising data coming out of ASCO 2017 in Chicago, IL. He discusses several trials for treatment of advanced intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC)

William P. Harris, MD of Seattle Cancer Care Alliance discusses the treatment trends for upper gastrointestinal cancers, which include targeted therapy and immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

William P. Harris, MD of Seattle Cancer Care Alliance explains some of the common questions asked regarding the phase II trial on pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

William P. Harris, MD of Seattle Cancer Care Alliance discusses metastatic pancreatic cancer for the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4008: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

Julie R. Gralow, MD of Seattle Cancer Care Alliance gives an overview of her presentation, SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy

Julie R. Gralow, MD of Seattle Cancer Care Alliance explains the impact of the trial on clinical practice, arguing that the data now shows the important role PARP inhibitors have in metastatic breast cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 521: SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy

Davendra Sohal, MD of Cleveland Clinic discusses the treatment trends for pancreatic cancer, which include understanding the mechanisms of resistance to current therapies. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Davendra Sohal, MD of Cleveland Clinic discusses the impact of perioperative chemotherapy on management of resectable pancreatic cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Davendra Sohal, MD of Cleveland Clinic gives an overview of his presentation, Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. TPS4152: Perioperative mFOLFIRINOX vs. Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and ipilimumab combination in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of his hopes for the expansion of talimogene laherparepvec across multiple cancer types for future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the most exciting and interesting presentations coming out of ASCO 2017, which include three oral presentations, focusing on the efficacy of FDA-approved combination regiments in melanoma patients who have brain metastases. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask regarding his study on talimogene laherparepvec and ipilimumab in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma

Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance explains the impact of natural language processing (NLP) on future clinical practice and trials. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).

Bernardo H. Goulart, MD, MS of Seattle Cancer Care Alliance discusses the use of natural language processing (NLP) for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6528: Validation of natural language processing (NLP) for automated ascertainment of EGFR and ALK tests in SEER cases of non-small cell lung cancer (NSCLC).

Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of his current clinical studies, which focus on the use of mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer patients Abstract 5547: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts Abstract TPS5607: FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FR?)-positive, platinum-resistant…

Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center discusses a collaborated study with Dr. Dr. Jalid Sehouli of AGO and Charité Campus Virchow-Klinikum, Berlin, Germany, that focuses on the clinical characteristics of long-term ovarian cancer survivors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract e17063: Clinical characterization of long term survivors (LTS) in ovarian cancer (OC): Results of a propensity score matched (PSM) analysis of the international prospective tumor bank for ovarian cancer (TOC Network)

Michael J. Birrer, MD, PhD discusses his role as newly appointed director for the University of Alabama at Birmingham Comprehensive Cancer Center and his future plans and goals for the hospital. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of presentation that involves the use of avelumab in patients with endometrial cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS5615: Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer

Manmeet S. Ahluwalia, MD of Cleveland Clinic discusses three abstracts presented at ASCO 2017, highlighting the management of brain metastases in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9506: COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600mutant (mut) melanoma brain metastases (MBM) presented by Dr. Michael A. Davies of MD Anderson Cancer Center Abstract 9507: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204 presented by…

Manmeet S. Ahluwalia, MD of Cleveland Clinic gives an overview of his presentation, What Drives Patient Outcomes in Brain Metastases: Number, Volume, or Biology, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 2071: What Drives Patient Outcomes in Brain Metastases: Number, Volume, or Biology?

Vivek Subbiah, MD of MD Anderson Cancer Center discusses the impact of his study of vemurafenib in NSCLC patients on clinical practice and future clinical research. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.

Vivek Subbiah, MD of MD Anderson Cancer Center discusses the exciting and new data presented at ASCO, which shows promise for the future of precision oncology and personalized therapy. This was recorded at the 2017 ASCO Annual Meeting.

Vivek Subbiah, MD of MD Anderson Cancer Center gives an overview of his presentation, which focused on the use of vemurafenib in patients with non small-cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9074: Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600mutation.

Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of his presentation, which focused on the difference between left and right sided tumors in patients with colon cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Alan P. Venook, MD of UCSF Helen Diller Family Comprehensive Cancer Center gives an overview of the exciting presentations discussed at ASCO this year. One particular presentation he is most interested in focuses on the treatment of stage III colon cancer with adjuvant therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the common questions and concerns regarding her presentation on commercially prescribed PD-1 inhibitors in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute gives an overview of her presentation, Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9087: Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.

Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute discusses the treatment trends for lung cancer and oncology overall, which include combination therapy and immune checkpoint inhibitors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Alok Khorana, MD of Cleveland Clinic gives an overview his presentation, which focuses on time to initiating (TTI) cancer therapy for common solid tumors. Data suggests an increase in TTI is associated with substantial increase in mortality. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 6557: Time To Initiating Cancer Therapy Is Increasing And Associated With Worsened Survival In Curative Settings: A US Analysis of Common Solid Tumors

Alok Khorana, MD of Cleveland Clinic discusses the skepticism surrounding timing to initiating (TTI) cancer therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Alok Khorana, MD of Cleveland Clinic gives an overview of the treatment trends for gastrointestinal cancers, which includes the use of adjuvant therapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of the treatment trends for non-small cell lung cancer for 2017, which include new approvals for immunotherapies. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL

Daniel A. Goldstein, MD of Davidoff Cancer Center discusses the impact of weight-based dosing on patients’ affordability of the drug. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL

Daniel A. Goldstein, MD of Davidoff Cancer Center explains the questions regarding the equivalence of dosing in milligrams versus milligrams per kilograms. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer.

Daniel A. Goldstein, MD of Davidoff Cancer Center gives an overview of his presentation, involving dosing of pembrolizumab in non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9013: A phamacoeconomic analysis of personalized dosing versus fixed dosing of pembrolizumab in first-line PD-L1 positive non-small cell lung cancer

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the challenges of the AIM2CERV trial at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the take-home message coming out of ASCO 2017, which includes the breakthrough of immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the importance of targeting HPV-associated cancers. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center explains the goal of the AIM2CERV trial, which is to evaluate whether or not axalimogene filolisbac can prevent or reduce the risk of cervical cancer recurrence after patients received the initial standard of care. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the use of AIM2CERV’s axalimogene filolisbac for the treatment of HPV-associated cancers, including cervical cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center gives an overview of his presentation, AIM2CERV: Global Phase 3 Trial of Advaxis Axalimogene Filolisbac for Cervical Cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the impact of the AIM2CERV study on patients with cervical cancer and on clinical practice. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the most common questions he has been asked regarding the ENCORE study, which are: what are the characteristics of the patients that went into the study, how long has it been since the patients progressed, and are these patients who initially had a response and then progress? This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of a few presentations that he finds the most promising from the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma, which was discussed at the 2017 ASCO Annual Meeting in Chicago, IL.

Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the treatment trends in 2017 for advanced melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Krishnansu S. Tewari, MD of University of California, Irvine explains what CA4P is. CA4P is a vascular disrupting agent (VDA), which is thought to work by blocking the blood supply inside the tumor, depriving it of oxygen and nutrients, which leads to cell death. CA4P is being developed by Mateon Therapeutics in South San Francisco, CA. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Krishnansu S. Tewari, MD of University of California, Irvine discusses the most recent results from the FOCUS trial, including the first interim analysis which evaluated the safety of the drug as well as early signs of efficacy. The trial is sponsored by Mateon Therapeutics in South San Francisco, CA This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Krishnansu S. Tewari, MD of University of California, Irvine gives an overview of the FOCUS trial, which is sponsored by Mateon Therapeutics in South San Francisco, CA. The FOCUS trial is a double-blind, randomized, phase 2/3 clinical study evaluating the efficacy and safety of physicians choice chemotherapy plus bevacizumab and CA4P versus physicians choice chemotherapy plus bevacizumab and placebo in patients with platinum-resistant ovarian cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL

Krishnansu S. Tewari, MD of University of California, Irvine discusses the impact of the FOCUS trial on clinical practice, explaining how the trial gives ovarian cancer patients another option for treatment.

Mark Rutstein, Vice President of Oncology Development of Bayer discusses the xofigo injection, a treatment method for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of three abstracts that discussed the use of regorafenib (stivarga) in advanced colorectal cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #3567: Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study Abstract #3551: Handfoot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC) Abstract #4078: Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in…

Mark Rutstein, Vice President of Oncology Development of Bayer discusses his take on the treatment trends for 2017 and 2018, which include the growth of immunotherapy and therapy tailored to individual patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark Rutstein, Vice President of Oncology Development of Bayer discusses the RIFTOS trial, which focused on the use of sorafenib for thyroid cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #6084: Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of two poster presentations that focus on the use of Copanlisib for relapsed or refractory follicular lymphoma and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Poster #7535: Copanlisib in patients with relapsed or refractory follicular lymphoma Poster #7536: Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Mark Rutstein, Vice President of Oncology Development of Bayer discusses Bayers current and approved products and new and diverse advances for its robust oncology pipeline. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Mark Rutstein, Vice President of Oncology Development of Bayer gives an overview of the ARASENS study, which is a phase 3 trial on the use of darolutamide for men with metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract #TPS5092: ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)